Login to Your Account



Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III

By Catherine Shaffer


Thursday, March 31, 2011
Amgen Inc. and Takeda Pharmaceutical Co. Ltd. shared their disappointment today regarding top-line results of a Phase III trial of their VEGF inhibitor, motesanib, for nonsquamous non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription